Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor TD-1473 showed a reduction in plasma exposure compared to?currently-approved JAK inhibitor. On June 9, 2016, Theravance Biopharma released positive results from a completed Phase I clinical trial of TD-1473, its oral GI-targeted pan-Janus kinase (JAK) inhibitor. TD-1473 is[…]
In Brief Biosimilar News reports that Sorrento’s experimental anti-IgE biosimilar, STI-004, met it’s primary endpoint in a 32-week, Phase 2/3 study conducted in China. ?Patients who received?STI-004 experienced?asthma exacerbation at a lower rate than those who received placebo: ?21% vs?55%. According to the Sorrento press release, the patient population included both?adult and adolescents suffering from[…]
Smart Bottle?Pharmacy Delivery Service According to a new report in Forbes, the start-up,?Circadian Design, has?innovated medication, vitamin, and refill reminders by combining a few old ideas. ?The new service is called?Round Refill?and?the reminders are generated?via a connection between a medication?bottle cap and?an app on your mobile.?? Pre-Ordering Available Business Wire is reporting that “Round[…]